TITLE

SIMCERE PHARMACEUTICAL AQUIRES 70% STAKE IN WUHU ZONG REN

PUB. DATE
June 2008
SOURCE
Worldwide Biotech;Jun2008, Vol. 20 Issue 6, p8
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
This article reports on a definitive agreement signed by Simcere Pharmaceutical Group to acquire an equity interest in Wuhu Zhong Ren Pharmaceutical Co. This transaction is consistent with the strategy of Simcere to focus on first-to-market and innovative new drugs and expand its anti-cancer product portfolio. WuHu Zhong is a Chinese drug manufacturer specializing in the production of sustained release anti-tumor implants.
ACCESSION #
32474192

 

Related Articles

  • Tigermed Cooperates with Simcere in Drugs R&D.  // China Chemical Reporter;12/26/2009, Vol. 20 Issue 36, p13 

    The article announces the partnership agreement signed by the leading Contract Research Organization (CRO) Tigermed Consulting Co. Ltd. and Jiangsu Simcere Pharmaceutical Group in China. It states that the agreement will see the two companies to collaborate in many aspects pertaining to medicine...

  • Amgen to pay $2.2B for Abgenix. Jarvis, Lisa // Chemical Market Reporter;12/19/2005, Vol. 268 Issue 20, p4 

    This article reports that Amgen Inc., has planned to buy its will pay drug development partner Abgenix Inc. by offering $2.2 billion in cash. Share prices of Abgenix increase upto 48 percent to close at $21.69 last Thursday. The transaction is expected to close at the end of the first quarter of...

  • This week in BioWorld Asia.  // BioWorld Today;1/2/2013, Vol. 25 Issue 1, p1 

    A list of topics featured in the journal "BioWorld Asia" in January 2014 is presented including the plans of the Chinese government to relaunch its biopharmaceutical market, the privatization of Simcere Pharmaceutical Group, and the partnership of China's drug importer with BioCubaFarma.

  • Cardiology Sector to Boom.  // Chain Drug Review;1/16/2012, Vol. 34 Issue 2, p61 

    The article offers various information related to cardiology in the U.S. including the U.S. Food and Drug Administration's (FDA's) approval to Edarbyclor, the expansion of the partnership between Simcere Pharmaceutical Group and Bristol-Myers Squibb Co., and prediction for anticoagualants' boost.

  • Simcere Pharmaceutical Receives $500M Proposal to Go Private. COLLINS, ALLISON // Mergers & Acquisitions Report;3/18/2013, Vol. 26 Issue 11, p4 

    The article reports on a 500 million U.S. dollars buyout offer received by Simcere Pharmaceutical Group from the chairman of its board of directors, Jinsheng Ren.

  • Fresh from the pipeline: Gefitinib. Muhsin, Mohamed; Graham, Joanne; Kirkpatrick, Peter // Nature Reviews Drug Discovery;Jul2003, Vol. 2 Issue 7, p515 

    Gefitinib (Iressa; AstraZeneca) is the first in a new class of targeted anticancer drugs that inhibit the tyrosine kinase activity of the epidermal growth factor receptor. Following Japanese approval in 2002, gefitinib was approved by the US FDA in May 2003 for the treatment of advanced...

  • In this issue.  // Nature Reviews Drug Discovery;Nov2010, Vol. 9 Issue 11, p821 

    The article discusses various reports published within the issue, including one by Brinkmann and colleagues on the case history of fingolimod, one by Cohen on cyclical development strategy, and one by Doroshow and colleagues on their evaluation of anticancer agents at the U.S. National Cancer...

  • Anticancer chemotherapy. Davey, Peter; Tudhope, G.R. // British Medical Journal (Clinical Research Edition);7/9/1983, Vol. 287 Issue 6385, p107 

    Features several of the latest cytotoxic drugs and its applications in Great Britain. Current drugs and their analogues; Developments with antimetabolites; Enumerations on latest cytotoxic drugs.

  • Vidaza, Dacogen Slug It Out; Is Celgene Paying Too Much? Osborne, Randall // BioWorld Financial Watch;12/3/2007, Vol. 15 Issue 49, p1 

    The article reports on the outcome of a deal entered by Celgene Corp. to acquire Pharmion Corp. in 2007. The deal boosted the presence of Celgene in the worldwide hematology and cancer markets. Under the deal, Celgene gets full rights to Thalomid (thalidomide) for multiple myeloma and...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics